Inactivated Autograft-prosthesis Composite Has a Role for Grade III Giant Cell Tumor of Bone Around the Knee

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2013 Nov 12

PMID 24209887

Citations 9

Authors

Songfeng Xu

Xiuchun Yu

Ming Xu

Zhihou Fu

Affiliations

Soon will be listed here.

Abstract

Background: Giant cell tumors (GCT) around the knee are common and pose a special problem of reconstruction after tumor excision, especially for grade III GCT. We questioned whether en bloc resection and reconstruction with alcohol inactivated autograft-prosthesis composite would provide (1) local control and long-term survival and (2) useful limb function in patients who had grade III GCT around the knee.

Methods: We retrospectively reviewed eight patients (5 males and 3 females) treated with this procedure with mean age of 31 years (range 20 to 43 years) from Jan 2007 to Oct 2008. 5 lesions were located in distal femur and 3 in proximal tibia. 4 patients were with primary tumor and the other 4 with recurrence. 2 patients showed pathological fracture.

Results: Mean Follow-up is 54 months ranging from 38 to 47 months. No recurrence, metastasis, prosthesis loosening were found. The mean healing time between autograft and host bone was 5.5 months. The mean MSTS score was 26.3 (88%) ranging from 25 to 29. The mean ISOLS composite graft score was 32.8 (88.5%) ranging from 28 to 35. Creeping substitution is possibly the main way in bony junction. The healing time in femoral lesion is faster than that in tibial lesion.

Conclusions: The technique of alcohol inactivated autograft-prosthesis composite could be able to achieve satisfactory oncological and functional outcomes in Grade III GCT.

Citing Articles

Case Report: Three-dimensional printed prosthesis reconstruction for patello-femoral large osteochondral defects in a patient with distal femoral giant cell tumour: A case report.

Yuan D, Fang X, Lei S, Banskota N, Kuang F, Gou Y Front Bioeng Biotechnol. 2022; 10:995879.

PMID: 36213058 PMC: 9532597. DOI: 10.3389/fbioe.2022.995879.

Reduction of metal artifacts from knee tumor prostheses on CT images: value of the single energy metal artifact reduction (SEMAR) algorithm.

Zhang F, Li R, Zhang X, Zhang Z, Ma L, Ding L BMC Cancer. 2021; 21(1):1288.

PMID: 34856926 PMC: 8638139. DOI: 10.1186/s12885-021-09029-3.

Use of three-dimensional-printed custom-made prosthesis to treat unicondylar femoral defect secondary to pathological fracture caused by giant cell tumor.

Ji Y, Wu Y, Li J J Int Med Res. 2021; 49(7):3000605211025347.

PMID: 34212773 PMC: 8255586. DOI: 10.1177/03000605211025347.

Comparative efficacy of intraoperative extracorporeal irradiated and alcohol-inactivated autograft reimplantation for the management of osteosarcomas-a multicentre retrospective study.

Xu M, Xu M, Zhang S, Li H, Qiuchi A, Yu X World J Surg Oncol. 2021; 19(1):157.

PMID: 34039361 PMC: 8157677. DOI: 10.1186/s12957-021-02271-w.

Alcohol Devitalization and Replantation for Primary Malignant Bone Tumors of the Knee Joint.

Zhang X, Chen G, Wang J, Tang L, Yin Y Iran J Public Health. 2018; 46(10):1318-1323.

PMID: 29308374 PMC: 5750342.

References

Jeon D, Kim M, Cho W, Song W, Lee S . Pasteurized autograft-prosthesis composite for distal femoral osteosarcoma. J Orthop Sci. 2007; 12(6):542-9. DOI: 10.1007/s00776-007-1173-7. View

Nishida J, Shimamura T . Methods of reconstruction for bone defect after tumor excision: a review of alternatives. Med Sci Monit. 2008; 14(8):RA107-13. View

Lietman S, Joyce M . Bone sarcomas: Overview of management, with a focus on surgical treatment considerations. Cleve Clin J Med. 2010; 77 Suppl 1:S8-12. DOI: 10.3949/ccjm.77.s1.02. View

Biau D, Dumaine V, Babinet A, Tomeno B, Anract P . Allograft-prosthesis composites after bone tumor resection at the proximal tibia. Clin Orthop Relat Res. 2006; 456:211-7. DOI: 10.1097/BLO.0b013e31802ba478. View

Prosser G, Baloch K, Tillman R, Carter S, Grimer R . Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone?. Clin Orthop Relat Res. 2005; (435):211-8. DOI: 10.1097/01.blo.0000160024.06739.ff. View

Vidyadhara S, Rao S . Techniques in the management of juxta-articular aggressive and recurrent giant cell tumors around the knee. Eur J Surg Oncol. 2006; 33(2):243-51. DOI: 10.1016/j.ejso.2006.05.023. View

Harrington K, Johnston J, Kaufer H, Luck Jr J, Moore T . Limb salvage and prosthetic joint reconstruction for low-grade and selected high-grade sarcomas of bone after wide resection and replacement by autoclaved [corrected] autogeneic grafts. Clin Orthop Relat Res. 1986; (211):180-214. View

Sung H, Wang H, Kuo D, Hsu W, Tsai Y . EAR method: an alternative method of bone grafting following bone tumor resection (a preliminary report). Semin Surg Oncol. 1986; 2(2):90-8. DOI: 10.1002/ssu.2980020205. View

Ghert M, Rizzo M, Harrelson J, Scully S . Giant-cell tumor of the appendicular skeleton. Clin Orthop Relat Res. 2002; (400):201-10. DOI: 10.1097/00003086-200207000-00025. View

10.

Yang Z, Tao H, Yang D, Ye Z, Li W . [The choice strategy of surgical treatment for giant cell tumor close to the knee]. Zhonghua Wai Ke Za Zhi. 2007; 44(24):1693-8. View

11.

Yu X, Xu M, Song R, Fu Z, Liu X . Long-term outcome of giant cell tumors of bone around the knee treated by en bloc resection of tumor and reconstruction with prosthesis. Orthop Surg. 2011; 2(3):211-7. PMC: 6583203. DOI: 10.1111/j.1757-7861.2010.00089.x. View

12.

Campanacci M, Baldini N, Boriani S, Sudanese A . Giant-cell tumor of bone. J Bone Joint Surg Am. 1987; 69(1):106-14. View

13.

Lackman R, Hosalkar H, Ogilvie C, Torbert J, Fox E . Intralesional curettage for grades II and III giant cell tumors of bone. Clin Orthop Relat Res. 2005; 438:123-7. DOI: 10.1097/01.blo.0000180051.27961.c3. View

14.

Poffyn B, Sys G, Van Maele G, Van Hoorebeke L, Forsyth R, Verstraete K . Radiographic analysis of extracorporeally irradiated autografts. Skeletal Radiol. 2010; 39(10):999-1008. DOI: 10.1007/s00256-010-0889-1. View

15.

Gilbert N, Yasko A, Oates S, Lewis V, Cannon C, Lin P . Allograft-prosthetic composite reconstruction of the proximal part of the tibia. An analysis of the early results. J Bone Joint Surg Am. 2009; 91(7):1646-56. DOI: 10.2106/JBJS.G.01542. View

16.

ENNEKING W, Dunham W, Gebhardt M, Malawar M, Pritchard D . A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993; (286):241-6. View

17.

Donati D, Colangeli M, Colangeli S, Di Bella C, Mercuri M . Allograft-prosthetic composite in the proximal tibia after bone tumor resection. Clin Orthop Relat Res. 2008; 466(2):459-65. PMC: 2505118. DOI: 10.1007/s11999-007-0055-9. View

18.

Wunder J, Leitch K, Griffin A, Davis A, Bell R . Comparison of two methods of reconstruction for primary malignant tumors at the knee: a sequential cohort study. J Surg Oncol. 2001; 77(2):89-99; discussion 100. DOI: 10.1002/jso.1076. View

19.

Eckardt J, Grogan T . Giant cell tumor of bone. Clin Orthop Relat Res. 1986; (204):45-58. View

20.

Song W, Cho W, Jeon D, Kong C, Duo J, Lee S . A comparison of tumor prosthesis implantation and pasteurized autograft-prosthesis composite for proximal tibial tumor. J Orthop Sci. 2012; 17(4):457-63. DOI: 10.1007/s00776-012-0224-x. View